USA flag logo/image

An Official Website of the United States Government

RECOMBINANT CNTF FOR TREATMENT OF NEUROPATHIES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16251
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16251
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
California Biotechnology, Inc.
2450 Bayshore Parkway Mountain View, CA 94043
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: RECOMBINANT CNTF FOR TREATMENT OF NEUROPATHIES
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

CILIARY NEUROTROPHIC FACTOR (CNTF) IS A POTENT POLYPEPTIDE HORMONE WHOSE ACTIONS APPEAR TO BE RESTRICTED TO THE NERVOUS SYSTEM. CNTF HAS BEEN OBSERVED TO PROMOTE SURVIVAL, NEUROTRANSMITTER SYNTHESIS AND NEURITE OUTGROWTH IN VARIOUS SYMPATHETIC, SENSORY AND PARASYMPA- THETIC NEURONS AT FEMTOMOLAR TO LOW PICOMOLAR CONCENTRATIONS. THUS CNTF HAS POTENTIAL CLINICAL APPLICATIONS IN THE TREATMENT OF A NUMBER OF DIFFERENT NEUROPATHIES AND NEURODEGENERATIVE DISORDERS IN MAN AS WELL AS IN THE TREATMENT OF TRAUMATIC NERVE INJURY. IT IS THE GOAL OF THIS PROJECT TO ASSESS THIS POTENTIAL BY FIRST PROVIDING A SOURCE OF HUMAN CNTF USING RECOMBINANT DNA METHODS (PHASE I) AND THEN USING THIS SOURCE TO ESTABLISH EFFICACY IN SPECIFIC ACUTE ANIMAL MODELS OF PERIPHERAL NEUROPATHIES (PHASE II) AND, IF INDICATED, IN HUMAN CLINICAL TRIALS (PHASE III).

Principal Investigator:

Barbara Cordell
Principal Investigator
4159661550

Business Contact:

1 r43 ag09705-01
Small Business Information at Submission:

California Biotechnology, Inc
2450 Bayshore Parkway Mountain View, CA 94043

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No